June 13th 2024
Minoo Battiwalla, MD, MS, discusses the impact of earlier-line FDA approvals for CAR T-cell therapies on treatment outcomes in multiple myeloma.
June 11th 2024
Clinical benefit generated from treatment with lurbinectedin plus irinotecan was noted across sensitive and resistant patient populations with SCLC.
Axi-cel administration was safe and clinically active in relapsed/refractory primary and secondary central nervous system lymphoma.
The strength of mKRAS-specific T-cell responses produced by ELI-002 7P correlated with tumor biomarker responses in pancreatic and colorectal cancer.
May 28th 2024
Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia.
From barely escaping a life under communism in a Russia-occupied Latvia to overcoming a family health crisis, Robert F. Ozols, MD, PhD, knows a thing or two about beating the odds.
May 24th 2024
Sanjal Desai, MD, expands on the safety, efficacy, and sequencing of BTK inhibitors and venetoclax-based regimens in chronic lymphocytic leukemia.
James Ignatz-Hoover, MD, PhD, discusses the evolving use of CAR T-cell therapies and bispecific antibodies in multiple myeloma.
Stephen V. Liu, MD, details the phase 1/2 ARROS-1 study evaluating the selective ROS1 inhibitor zidesamtinib in patients with ROS1 fusion–positive non–small cell lung cancer.
Marketing authorization applications for the denosumab biosimilar HLX14 have been validated by the EMA.
May 23rd 2024
Petros Grivas, MD, PhD, expands on key updates in the second-line management of urothelial cancer.
May 22nd 2024
Peter H. O’Donnell, MD, provides insights on key developments in bladder cancer management and how they have generated optimism within the field.
May 20th 2024
WU-CART-007 has received RMAT and PRIME designations in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
May 17th 2024
Dose reductions of ribociclib plus an NSAI did not decrease the regimen’s efficacy in patients with HR-positive, HER2-negative early breast cancer.
NVL-655 has received FDA breakthrough therapy designation for patients with pretreated ALK-positive non-small cell lung cancer.
May 16th 2024
Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.
May 15th 2024
Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant, ER-positive, HER2-negative breast cancer.
May 14th 2024
Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.
May 13th 2024
The FDA has granted breakthrough therapy designation to petosemtamab in recurrent or metastatic head and neck squamous cell carcinoma.
May 10th 2024
Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.